Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...

Abbott has been given U.S. clearance for new updates to its CardioMEMS HF System that allow for patient-facing capabilities ...

Using a short lapidated peptide (SLiP) developed by Mimetic Medicines disrupted a crucial voltage-gated sodium channel ...

A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.

Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival ...

Forbion has touted its “landmark” 2.3 billion euro ($2.6 billion) fundraise across two funds as a new record for the European ...

Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...

Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...

Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...

Knowing how to choose a biologics CDMO matters as it’s one of the most important strategic decisions any biotech or biopharma ...

Eli Lilly has been pushing at an open door by tacking on $870 million in biobucks to its existing collaboration with Gate Bioscience. | Eli Lilly has been pushing at an open door by tacking on $870 ...

Author: Matt Lawton, Executive Director, FSP Delivery, Syneos Health | Why Your Operating Model Should Reflect Your Company’s ...